Fondaparinux effective and well-tolerated for prevention of VTE in acutely ill patients

News
Article

Fondaparinux (Arixtra, Organon/Sanofi-Synthelabo) given once daily significantly reduces the risk of venous thromboembolism (VTE) in acutely ill, hospitalized patients, according to data from the Arixtra for ThromboEmbolism prevention in a Medical Indications Study (ARTEMIS).

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.